ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an update.
Global growth is expected to decline and downside risks to intensify as major policy shifts unfold After enduring a prolonged and unprecedented series of shocks, the global economy appeared to have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback